Therapeutic Strategy Details
| Strategy ID: | S06 |
| Strategy: | Regulating intestinal flora |
| Other Terms: | intestine gut microbiota; gut microbiota |
| Related Targets: | farnesoid X receptor (FXR); fibroblast growth factor-19 (FGF19) |
| Related Drugs: | Probiotics; Prebiotics; Rifaximin; Yaq-001; Cilofexor; EDP-305; EYP001a; INT-767 |
| Mechanism: | An altered microbiome (“dysbiosis”) may contribute to liver damage. Human studies document a fecal microbiome signature characterized by increased Proteobacteria and Bacteroidetes along with a decrease in Firmicutes in patients with obesity and NASH. |
| Reference (PMIDs): | 15942443; 28257306; 28774887 |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Drug ID | Drug Name | Type | DrugBank ID | Targets | Category | Latest Progress |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A00030 | 35250593 | Front Pharmacol | Combined Use of Bicyclol and Berberine Alleviates Mouse Nonalcoholic Fatty Liver Disease. | Details |
| A00038 | 35248539 | Gastroenterology | NAFLD and the Gut-Liver Axis: Exploring an Undernutrition Perspective. | Details |
| A00075 | 35229847 | Food Funct | N-Acetylcysteine alleviates high fat diet-induced hepatic steatosis and liver injury via regulating the intestinal microecology in mice. | Details |
| A00094 | 35222044 | Front Pharmacol | Antibiotic Disruption of the Gut Microbiota Enhances the Murine Hepatic Dysfunction Associated With a High-Salt Diet. | Details |
| A00113 | 35216439 | Int J Mol Sci | Heat-Inactivated Akkermansia muciniphila Improves Gut Permeability but Does Not Prevent Development of Non-Alcoholic Steatohepatitis in Diet-Induced Obese Ldlr-/-.Leiden Mice. | Details |
| A00181 | 35195774 | Arch Microbiol | A review on the effect of gut microbiota on metabolic diseases. | Details |
| A00229 | 35174500 | J Sci Food Agric | Identification of a novel probiotic and its protective effects on NAFLD via modulating gut microbial community. | Details |
| A00265 | 35160340 | J Clin Med | Effects of Moderate Alcohol Consumption in Non-Alcoholic Fatty Liver Disease. | Details |
| A00269 | 35159371 | Cells | The Origins of NAFLD: The Potential Implication of Intrauterine Life and Early Postnatal Period. | Details |
| A00288 | 35152443 | J Food Sci | Bentong ginger oleoresin mitigates liver injury and modulates gut microbiota in mouse with nonalcoholic fatty liver disease induced by high-fat diet. | Details |
| A00315 | 35141703 | Front Oral Health | Diet-Induced Non-alcoholic Fatty Liver Disease and Associated Gut Dysbiosis Are Exacerbated by Oral Infection. | Details |
| A00341 | 35127789 | Front Nutr | Lentinan Supplementation Protects the Gut-Liver Axis and Prevents Steatohepatitis: The Role of Gut Microbiota Involved. | Details |
| A00369 | 35115689 | Nat Genet | Combined effects of host genetics and diet on human gut microbiota and incident disease in a single population cohort. | Details |
| A00384 | 35108315 | PLoS One | Gut microbiota and butyrate contribute to nonalcoholic fatty liver disease in premenopause due to estrogen deficiency. | Details |
| A00389 | 35104782 | Ecotoxicol Environ Saf | Chronic lead exposure induces fatty liver disease associated with the variations of gut microbiota. | Details |
| A00450 | 35077907 | Environ Toxicol Pharmacol | Enterobacter cloacae aggravates metabolic disease by inducing inflammation and lipid accumulation. | Details |
| A00517 | 35054847 | Int J Mol Sci | The Intestinal Barrier and Its Dysfunction in Patients with Metabolic Diseases and Non-Alcoholic Fatty Liver Disease. | Details |
| A00526 | 35053205 | Biomolecules | Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives. | Details |
| A00533 | 35052765 | Biomedicines | Bifidobacterium bifidum Shows More Diversified Ways of Relieving Non-Alcoholic Fatty Liver Compared with Bifidobacterium adolescentis. | Details |
| A00549 | 35050187 | Metabolites | The Interaction between the Gut Microbiome and Bile Acids in Cardiometabolic Diseases. | Details |